0001493152-19-001476.txt : 20190315 0001493152-19-001476.hdr.sgml : 20190315 20190206170508 ACCESSION NUMBER: 0001493152-19-001476 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20190206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2117 SW HIGHWAY 484 CITY: OCALA STATE: FL ZIP: 32801 BUSINESS PHONE: 215-988-0080 MAIL ADDRESS: STREET 1: 2117 SW HIGHWAY 484 CITY: OCALA STATE: FL ZIP: 32801 CORRESP 1 filename1.htm


	SILVERMAN SHIN & BYRNE PLLC	New Jersey
	Wall Street Plaza	19 Engle Street
	22nd Floor	Tenafly, NJ 07670
	88 Pine Street	(201) 567-4969
	NEW YORK, NY 10005
	212.779.8600
	Facsimile: 212.779.8858

February 6, 2019

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

	Re:	Hemispherx Biopharma, Inc.
		Registration Statement on Form S-1 (SEC File No. 333-229051)
		Filed with the Commission on December 27, 2018

Dear Sir or Madam:

On behalf of Hemispherx Biopharma, Inc. (the “Company”), we file herewith Amendment No. 1 to the above referenced registration statement. It contains all of the material terms of the rights offering.

As the Company’s financial statements go stale end of day on February 14, 2019, we anticipate requesting acceleration to that date.

If you have any questions, please contact me as soon as possible.

	Very truly yours,

	/s/ Richard Feiner
	Richard Feiner

cc: Hemispherx Biopharma, Inc.

GRAPHIC 2 image_001.jpg begin 644 image_001.jpg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end